Searchable abstracts of presentations at key conferences in endocrinology

ea0011p29 | Bone | ECE2006

Evaluation of bone markers and structure in subclinical Cushing’s syndrome

Monesi M , Ambrosio MR , Taroni S , Bondanelli M , Zatelli MC , degli Uberti EC

Overt hypercortisolism causes reduction in bone mass and density. The effects of subclinical Cushing’s syndrome (SCS) on bone markers and structure are still debated. We therefore studied 56 patients with adrenal incidentaloma: group A=35 (20 F 15 M, age 43–79, mean 64.6±1.5; BMI 29.9±0.9 kg/m2) without evidence of hypercortisolism, and group B=21 (10 F 11 M, age 51–76, mean 63.4±1.9, BMI 28.0±1.2 kg/m2) with SCS (i.e. w...

ea0011p461 | Endocrine tumours and neoplasia | ECE2006

Role of complex Cdk4/Cyclin D1 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro

Tagliati F , Zatelli MC , Bottoni A , Piccin D , Luchin A , Culler MD , degli Uberti EC

Somatostatin (SRIH) inhibits cell proliferation by interacting with five distinct SRIH receptor subtypes (SSTR) by several pathways in many tissues. We previously demonstrated that SRIH, by activating SHP-1, inhibits cell proliferation of the human Medullary Thyroid Carcinoma (MTC) cell line, TT, which expresses all SSTR. However, the effects of SRIH on cell cycle proteins have not been investigated, so far. We therefore investigated the effects of SRIH and of a selective SSTR...

ea0011p462 | Endocrine tumours and neoplasia | ECE2006

Selective Cyclo-oxygenase 2 inhibitors revert chemoresistance In Medullary thyroid carcinoma by a mechanism mediated by P-gp and PGH2

Zatelli MC , Luchin A , pICCIN D , Tagliati F , Bottoni A , Vignali C , Bondanelli M , degli Uberti EC

Medullary thyroid carcinoma (MTC) is a malignant tumour deriving from parafollicular C cells, with a highly chemoresistant phenotype. Failure of medical therapy has been ascribed, at least in part, to multi drug resistance (MDR1) gene over-expression. MDR1 encodes for a transmembrane glycoprotein, P-gp, which hampers intracellular accumulation of cytotoxic drugs. It has been demonstrated that P-gp expression and function depend on cyclo-oxygenase 2 (COX-2) expression, which is...